Cargando…

Peptidic microarchitecture-trapped tumor vaccine combined with immune checkpoint inhibitor or PI3Kγ inhibitor can enhance immunogenicity and eradicate tumors

BACKGROUND: With the rapid development of immune checkpoint inhibitors and neoantigen (NeoV)-based personalized tumor vaccines, tumor immunotherapy has shown promising therapeutic results. However, the limited efficacy of available tumor vaccines impedes the development of personalized tumor immunot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Yang, Liu, Ye, Wang, Di, Bai, Hua, Wang, Zhijie, He, Xiran, Zhang, Pei, Tian, Jie, Wang, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883272/ https://www.ncbi.nlm.nih.gov/pubmed/35217574 http://dx.doi.org/10.1136/jitc-2021-003564

Ejemplares similares

Host response to immune checkpoint inhibitors contributes to tumor aggressiveness
por: Khononov, Irina, et al.
Publicado: (2021)

ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma
por: Sheng, Hailong, et al.
Publicado: (2020)

Characterizing tumor shrinkage as a measure of clinical benefit for immune checkpoint inhibitors
por: Kelleher, Thomas, et al.
Publicado: (2021)

Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice
por: Pieper, Alexander A, et al.
Publicado: (2021)

Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung
por: Dudnik, Elizabeth, et al.
Publicado: (2021)

Immune checkpoint inhibitor-associated celiac disease
por: Badran, Yousef R, et al.
Publicado: (2020)

Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression
por: Pierini, Stefano, et al.
Publicado: (2021)

Electrocardiographic features of immune checkpoint inhibitor associated myocarditis
por: Zlotoff, Daniel A, et al.
Publicado: (2021)

Pericardial disease in patients treated with immune checkpoint inhibitors
por: Gong, Jingyi, et al.
Publicado: (2021)

Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis
por: Mooradian, Meghan J, et al.
Publicado: (2020)

Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression
por: Giroux Leprieur, Etienne, et al.
Publicado: (2020)

Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors
por: Fucà, Giovanni, et al.
Publicado: (2021)

Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma
por: Ho, Won Jin, et al.
Publicado: (2020)

Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis
por: Durbin, Sienna M, et al.
Publicado: (2020)

Acute kidney injury in patients treated with immune checkpoint inhibitors
por: Gupta, Shruti, et al.
Publicado: (2021)

Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis
por: Cautela, Jennifer, et al.
Publicado: (2020)

Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study
por: Reid, Pankti, et al.
Publicado: (2021)

Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series
por: Coustal, Cyrille, et al.
Publicado: (2023)

Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis
por: Li, Yanlin, et al.
Publicado: (2023)

Impact of immune checkpoint inhibitors on atherosclerosis progression in patients with lung cancer
por: Drobni, Zsofia Dora, et al.
Publicado: (2023)

Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors
por: Dolladille, Charles, et al.
Publicado: (2020)

Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors
por: Mamoor, Maha, et al.
Publicado: (2020)

Oral beclomethasone dipropionate is an effective treatment for immune checkpoint inhibitor induced colitis
por: Alexander, James L, et al.
Publicado: (2022)

Increased rates of immunosuppressive treatment and hospitalization after checkpoint inhibitor therapy in cancer patients with autoimmune disease
por: Bender, David Andrew, et al.
Publicado: (2020)

Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma
por: Bersanelli, Melissa, et al.
Publicado: (2023)

Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma
por: He, Xiran, et al.
Publicado: (2020)

Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma
por: Lee, Pei-Chang, et al.
Publicado: (2020)

Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors
por: Ahmed, Murtaza, et al.
Publicado: (2021)

Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors
por: Wong, Jeffrey Sum Lung, et al.
Publicado: (2021)

Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI
por: Gupta, Shruti, et al.
Publicado: (2022)

Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity
por: Abe, Shinya, et al.
Publicado: (2022)

Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancer
por: Qiu, Xin, et al.
Publicado: (2023)

Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors
por: Borchmann, Sven, et al.
Publicado: (2022)

Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response
por: Zhang, Lele, et al.
Publicado: (2021)

Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes
por: Meraz-Muñoz, Alejandro, et al.
Publicado: (2020)

Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival
por: Sussman, Tamara A, et al.
Publicado: (2021)

Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study
por: Bae, Seongman, et al.
Publicado: (2021)

Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab
por: Alexander, James L, et al.
Publicado: (2021)

Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis
por: Puzanov, Igor, et al.
Publicado: (2021)

Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma
por: Lee, Pei-Chang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m9cgkrissltf028kgtnrdjhpgb